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Purpose: To describe (1) the clinical profiles and the patterns of use of long-acting  injectable 
(LAI) antipsychotics in patients with schizophrenia at risk of nonadherence with oral 
 antipsychotics, and in those who started treatment with LAI antipsychotics, (2) health care 
resource utilization and associated costs.
Patients and methods: A total of 597 outpatients with schizophrenia at risk of nonadherence, 
according to the psychiatrist’s clinical judgment, were recruited at 59 centers in a noninterven-
tional prospective observational study of 1-year follow-up when their treatment was modified. 
In a post hoc analysis, the profiles of patients starting LAI or continuing with oral antipsychotics 
were described, and descriptive analyses of treatments, health resource utilization, and direct 
costs were performed in those who started an LAI antipsychotic.
Results: Therapy modifications involved the antipsychotic medications in 84.8% of patients, 
mostly because of insufficient efficacy of prior regimen. Ninety-two (15.4%) patients started an 
LAI antipsychotic at recruitment. Of these, only 13 (14.1%) were prescribed with first-generation 
antipsychotics. During 1 year, 16.3% of patients who started and 14.9% of patients who did not 
start an LAI antipsychotic at recruitment relapsed, contrasting with the 20.9% who had been 
hospitalized only within the prior 6 months. After 1 year, 74.3% of patients who started an LAI 
antipsychotic continued concomitant treatment with oral antipsychotics. The mean (median) total 
direct health care cost per patient per month during the study year among the patients starting 
any LAI antipsychotic at baseline was €1,407 (€897.7). Medication costs (including oral and LAI 
antipsychotics and concomitant medication) represented almost 44%, whereas nonmedication 
costs accounted for more than 55% of the mean total direct health care costs.
Conclusion: LAI antipsychotics were infrequently prescribed in spite of a psychiatrist-
perceived risk of nonadherence to oral antipsychotics. Mean medication costs were lower than 
nonmedication costs.
Keywords: health care costs, depot preparations, medication adherence
Introduction
Deviation from maintenance antipsychotic therapy remains a recurrent problem in 
the treatment of schizophrenia,1 represents a major difficulty in the management 
of the disease, and jeopardizes the achievement of relevant clinical outcomes.2–5 
Long-acting injectable (LAI) antipsychotics were developed specifically to promote 
adherence and enhance relapse prevention.6 Despite 50 years of clinical experience, 
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the knowledge base for examining their potential gains over 
oral  antipsychotics remains inconclusive7–10 and their use is 
confined to those patients who have suffered multiple relapses 
within the context of repeated episodes of nonadherence with 
antipsychotic medication.11
Among other factors, the limited availability of second-
generation LAI formulations12 and their high purchase 
costs13 have been commonly cited as reasons hampering LAI 
antipsychotic prescription. Currently, when the spectrum of 
second-generation LAI antipsychotics is growing after years 
of experience with risperidone as the single novel agent avail-
able, updated data on the clinical use of LAI antipsychotics, 
and the associated health care costs, are welcome.
The present paper reports the results of a naturalistic 
prospective research done in a cohort of outpatients with 
schizophrenia whose treatment was modified because of a 
physician-perceived risk of nonadherence to oral antipsy-
chotic therapy. Although this study put emphasis on evaluating 
the impact of therapeutic modifications on clinical outcomes 
in these patients, it also featured the secondary objective of 
providing comprehensive observational data on how LAI 
antipsychotics are initiated, what health care resources are 
utilized, and the total direct health care costs incurred by 
patients with schizophrenia switched to LAI antipsychotics. 
This article reports and comments the post hoc analyses and 
results related to this secondary objective.
Material and methods
Design and patients
This article concerns a post hoc exploratory analysis of the 
data collected in a 1-year prospective observational study of 
outpatients with schizophrenia according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision criteria who were considered to be at risk of 
nonadherence to oral antipsychotic medication by their treat-
ing psychiatrists. The primary objective was to evaluate the 
time to relapse in these patients undergoing any modification 
of their therapy,14 but this study also aimed to assess how 
LAI antipsychotics are started and used. The aforementioned 
post hoc analyses involved the description of the resources 
utilized and the direct health care costs of patients as a result 
of therapeutic challenges related to adherence issues after 
starting treatment with LAI antipsychotics. Results of these 
analyses are also provided.
Patients were recruited on the basis of a modification 
of their therapy related to a psychiatrist-perceived risk of 
nonadherence to oral antipsychotic medications, according 
to their best clinical judgment. To homogenize their  criteria, 
 psychiatrists were asked to identify one or more of the  following 
four features related to nonadherence in each patient: (1) poor 
insight, defined as a general total score $4 on the Scale to 
Assess Unawareness of Illness in Mental Disorders (SUMD);15 
(2) a negative attitude toward pharmacotherapy, defined as a 
score ,0 in the 10-item Drug Attitude Inventory (DAI-10);16 
(3) documented history of nonadherence; or (4) lack of effi-
cacy (documented clinical instability in the prior 6 months) or 
inadequate tolerability of current treatment.  Therapy modifica-
tions could be either a dose adjustment; change or addition in 
antipsychotic pharmacotherapy; any modification in the use 
of other selected concomitant psychotropic drugs commonly 
prescribed to patients with schizophrenia (anticholinergic, 
antidepressant, anxiolytic, hypnotic, and/or mood stabilizing 
agents); or the initiation, change, or removal of nonpharma-
cologic therapies (day center attendance, outpatient support 
services, rehabilitation, psychotherapy, psychoeducation, 
and others). Among the changes in antipsychotic medication, 
the start of an LAI formulation was a possibility. Patients 
already on LAI antipsychotics were excluded from the study, 
as it focused on how these medications are started and used 
afterwards. Therapeutic decisions were not altered due to 
study participation and were taken at the entire discretion of 
the treating physician and the patient.
Recruitment took place in 59 mental health community 
centers in Spain from February to May, 2008. To ensure 
sample representativity, the number of centers was propor-
tional to the updated regional census. All participants pro-
vided written informed consent and the study was approved 
by an ethical review board following applicable laws and 
regulations in Spain.
Treatment patterns and clinical 
evaluations
After the initial assessment, patients were evaluated again after 
approximately 3, 6, and 12 months, coinciding with their routine 
follow-up visits, and when they relapsed or withdrew from 
the study. The initial assessment included detailed data about 
therapy modifications for each of the three components men-
tioned, including the reasons suggested by treating  psychiatrists. 
Information on several known potential risk factors for non-
adherence and relapse was collected during a semistructured 
interview, including sociodemographic data, and psychiatric 
familial/personal history and comorbidities (Table 1). A battery 
of clinical instruments was also  administered. Among others, 
these included the Premorbid Adjustment Scale,17 the Clinical 
Global Impression scale-Severity (CGI-S),18 the DAI-10, and 
the SUMD. Total scores below and above 0 in the DAI-10 
Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
603
Use of long‑acting antipsychotics and health care resources
Table 1 subjects’ baseline characteristics according to prescription of long‑acting antipsychotics
Socio-demographic data Long-acting injectable  
antipsychotics  
(N = 92)
Oral antipsychotics  
(N = 505)
Total  
(N = 597)
Age, years [mean (sD)] 39.7 (11.1) 40.2 (11.2) 40.1 (11.1)
gender: proportion of males [n (%)] 59 (64.1) 321 (63.6) 380 (63.7)
Marital status: single [n (%)] 63 (68.5) 374 (74.1) 437 (73.2)
Patients with paid employment [n (%)] 16 (17.4) 115 (22.8) 131 (21.9)
Patients receiving social disability benefit [n (%)] 54 (58.7) 235 (46.5) 289 (48.4)
Clinical data
Age in the first episode, years [mean (SD)] 24.3 (5.4) 25.0 (7.2) 24.9(7.0)
Duration of untreated psychosis:
  ,3 months [n (%)] 19 (20.7) 133 (26.3) 152 (25.5)
  3 to 12 months [n (%)] 34 (37.0) 189 (37.4) 223 (37.4)
  .12 months [n (%)] 26 (28.3) 114 (22.6) 140 (23.5)
  Unknown [n (%)] 13 (14.1) 69 (13.7) 82 (13.7)
had more than 4 prior psychotic episodes [n (%)] 45 (48.9) 171 (33.9) 216 (36.2)
Familial history of psychiatric disorders [n (%)] 42 (45.7) 187 (37.0) 229 (38.4)
Past or current substance/alcohol use [n (%)] 34 (37.0) 146 (28.9) 180 (30.2)
hospitalized in prior 6 months [n (%)] 23 (25.0) 102 (20.2) 125 (20.9)
Psychiatric consultations in prior 6 months [mean (sD)] 5.1 (3.4) 4.7 (3.4) 4.7 (3.4)
Left duties unattended in prior 6 months [n (%)] 81 (88.0) 384 (76.0) 465 (77.9)
Scores of clinical instruments
PAs total/possible score [mean (sD)] 0.6 (0.2) 0.5 (0.2) 0.6 (0.2)
cgi‑s score [mean (sD)] 4.2 (0.8) 4.4 (0.8) 4.3 (0.8)
sAPs‑sAns total score [mean (sD)] 19.9 (6.3) 18.8 (7.0) 19.0 (6.9)
eQ‑5D quality of life [mean (sD)] 61.3 (24.1) 57.9 (20.5) 58.5 (21.1)
DAi‑10 total score [mean (sD)] -1.4 (5.2) 0.9 (5.2) 0.6 (5.3)
sUMD total score of awareness of disease [mean (sD)] 6.2 (1.6) 6.0 (1.7) 6.0 (1.7)
Abbreviations: cgi‑s, clinical global impression of severity; DAi‑10, 10‑item Drug Attitude inventory; eQ‑5D, euroQol‑5 Dimensions; PAs, Premorbid Adjustment scale; 
sAPs‑sAns, Abbreviated and combined versions of the scale for the Assessment of Positive symptoms and the scale for the Assessment of negative symptoms; sD, standard 
deviation; sUMD, scale to Assess the Unawareness of illness in Mental Disorders.
denoted negative and positive attitudes towards medication, 
respectively, and patients with a general score $4 on the first 
three items of the SUMD were considered to have a poor level 
of insight. At follow-up visits, the investigators updated the 
information on patients’ therapy and again administered the 
clinical instruments. Relapse was defined as the occurrence, at 
any time during follow-up, of either (1) worsening of psychiatric 
symptoms that led to a patient’s hospitalization or withdrawal 
from study, or (2) an increase equal to or greater than 1 point 
in the CGI-S that resulted in a score $4.
Patients’ patterns of antipsychotic prescription were 
evaluated to identify those who started treatment with an LAI 
antipsychotic. The aspects of LAI antipsychotic use evaluated 
included the proportion of patients concurrently treated with 
any oral antipsychotic, the duration of this concurrent use 
pattern, and doses and frequencies of treatment with each 
antipsychotic drug formulated as LAI.
resource utilization and cost
Health care resource utilization was evaluated at each assess-
ment point of the study. Structured abstraction forms were 
handled to participating psychiatrists to aid in this task. 
The information collected included the following three cost 
 components: (1) resources: hospitalizations (psychiatric hos-
pitals and general hospitals), emergency room, psychiatric 
outpatient consultations, other specialized outpatient consulta-
tions, visits to primary care services, skilled nursing facilities; 
(2) medications: antipsychotics and other psychotropic drugs; 
and (3) nonpharmacologic therapies: institutional support, asser-
tive community treatment/case management, psychoeducation, 
psychotherapy, rehabilitation, and management programs for 
severe mental illness. Nonmedical (informal) direct costs were 
disregarded. To estimate costs, average unit costs published for 
Spain,19 updated to reflect 2010 rates, were used for each of the 
resources ascertained; drug acquisition costs were assimilated 
to the weighted average retail price (plus value-added tax) per 
mg in the indication of schizophrenia and were calculated from 
the 2010 official registered prices.20 Another published source 
was used for the costs of nonpharmacologic therapies,21 which 
was supplemented with a Spanish database.22
Data analysis
All data were analyzed descriptively and used the observations 
available at each time point (missing data were not imputed). 
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This involved the calculation of descriptive statistics (means, 
medians, standard deviations, interquartile ranges, numbers, 
and frequencies) for study variables. Patients’ baseline char-
acteristics stratified by prescription of LAI antipsychotics were 
calculated in the whole sample. The doses of each LAI antip-
sychotic were described throughout the study for patients who 
started an LAI antipsychotic at baseline. The Kaplan–Meier 
method was used to describe the time to relapse (in all patients) 
and the duration of concurrent use of oral antipsychotics with 
LAI antipsychotics. The Kaplan–Meier method allowed for the 
estimation of the duration of concurrent use of oral antipsychot-
ics since the start of LAI antipsychotics, regardless of whether 
it was at baseline or during the study. Utilization of health care 
resources and mean direct health care cost components were 
assessed during the study year and expressed as mean and 
median averaged costs per month per patient for the 92 patients 
who started an LAI antipsychotic at baseline.
No sample size calculations were made in advance for 
these analyses. The sample size of the study was calculated at 
607 patients, to have sufficient power to analyze the primary 
objective concerning the time to relapse.
Results
Patient disposition, characteristics,  
and therapy modifications at baseline
Six hundred and twenty-eight patients were recruited. Thirty-
one were not analyzed because of the reasons provided 
in Figure 1. The remaining 597 formed the study cohort; 
566 patients completed the study.
Table 1 provides the descriptive statistics of patients’ 
characteristics. They showed an unfavorable clinical pro-
file, featuring severe psychopathology (CGI-S mean: 4.3, 
higher scores indicating more severity, scoring range: 1–7), 
frequent substance/alcohol use (30.2%) and hospitalizations 
Baseline (n = 597)
Month 3 (n = 583)
Month 6 (n = 573)
Month 12 (n = 566)
Lost to follow-up: 2
Widthdrew by investigator: 1
Consent withdrawal: 1
Lost to follow-up: 1
Left long-acting AP: 4
Left long-acting AP: 3
Started long-acting AP: 7 (8)a
Started long-acting AP: 8 (10)b
Started long-acting AP: 7
Long-acting AP: 92 (15.4%)
(79 ris, 6 flu, 7 zucl)
Long-acting AP: 94 (16.1%)
(79 ris, 6 flu, 9 zucl)
Long-acting AP: 98 (17.1%)
(79 ris, 7 flu, 12 zucl)
Long-acting AP: 105 (18.6%)
(85 ris, 9 flu, 11 zucl)
Oral AP: 505 (84.6%)
Oral AP: 489 (83.9%)
Oral AP: 475 (82.9%)
Oral AP: 461 (81.4%)
Did not meet selection criteria: 19
No follow-up data available: 12
Included: 628
Withdrew by investigator: 11
Left the study after relapse: 1
Withdrew by investigator: 2
Lost to follow-up: 5
Withdrew by investigator: 2
Consent withdrawal: 2
Lost to follow-up: 3
Figure 1 Patients’ disposition throughout the study.
Notes: Total patients starting LAI AP during the study: 114 (93 ris, 9 flu, 12 zucl). aOne patient left riseperidone LAI to start fluphenazine LAI; bone patient left riseperidone 
LAi to start Zuclopenthixol LAi and one patient left zuclopenthixol LAi to start risperidone LAi.
Abbreviations: AP, antipsychotics; flu, fluphenazine; ris, risperidone; zucl, zuclopenthixol.
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(20.9% within the prior 6 months), poor insight (SUMD total: 
6.0, higher scores indicating poorer insight, scoring range: 
0–9), and quality of life (EQ-5D mean quality of life: 58.5, 
higher scores indicating better quality of life, scoring range: 
0–100). Some of these characteristics, particularly patients’ 
subjective responses (attitudes) toward medications as mea-
sured with the DAI-10, differed between patients who started 
and did not start an LAI antipsychotic at baseline (Table 1).
Antipsychotic drugs were modified in 506 patients 
(84.8%), nonpharmacologic therapies were modified in 
190 patients (31.8%), and concomitant psychotropic medica-
tions were modified in 92 patients (15.4%). The most com-
mon reasons alleged for modifying antipsychotic drugs were 
lack of efficacy (64.8%), tolerability issues (14.2%), and 
prior history of nonadherence (13.8%). Nonpharmacologic 
therapies were modified because of insufficient effective-
ness (49.0%), lack of insight (32.1%), and documented 
nonadherence (11.6%).
effectiveness and relapse
During the study year, the CGI-S scores improved by 0.7 
points on average from baseline. In this period, 55 (9.2%) 
patients were hospitalized and 90 (15.1%) relapsed. The 
survival distribution function of the time to relapse (Figure 2) 
shows that relapses occurred at a constant pace throughout 
follow-up. The estimated cumulative incidence of relapse 
during 1 year, according to the Kaplan–Meier method was 
15.2%. This incidence seemed lower than the proportion 
of patients who had been hospitalized only in the preced-
ing 6 months (20.9%, Table 1). Relapse affected 16.3% of 
patients who started and 14.9% of patients who did not start 
an LAI antipsychotic at baseline.
Use of antipsychotics
LAI antipsychotics were started at baseline in 92 out of 
597 (15.4%) patients. The chosen agent was risperidone in 
most cases (79 patients, 85.9%), followed by fluphenazine 
(6 patients, 6.5%), and zuclopenthixol (7 patients, 7.6%). 
During the study year, 25 patients started (15 risperidone, 
4 fluphenazine, and 6 zuclopenthixol) and seven discontin-
ued LAI antipsychotics (Figure 1). Only eight out of these 
25 patients (32.0%) started the LAI antipsychotic within 
1 month after a relapse. Of 31 patients who withdrew pre-
maturely, five were on LAI treatment, giving a total of 105 
out of 566 patients (18.6%) on LAI antipsychotics by the 
study end. Throughout the study, the mean modal dose of 
LAI risperidone was 50 mg every 2 weeks, and about one 
quarter of patients received higher doses (Figure 3). The 
most common dosing regimens of LAI fluphenazine and 
zuclopenthixol were 25 mg every 3 weeks and 200 mg every 
3 weeks, respectively.
At baseline, 73 out of 92 patients who started an LAI 
antipsychotic (79.3%) maintained any concomitant oral antip-
sychotic drug (62 out of 79 patients started on LAI  risperidone, 
four out of six patients started on LAI  fluphenazine, and seven 
out of seven patients started on LAI zuclopenthixol). This pro-
portion was quite similar 1 year after (78 out of 105 patients 
on LAI antipsychotics, 74.3%). The 1-year Kaplan–Meier 
estimates of concurrent use of oral antipsychotics were of 
69.1% with LAI risperidone, 64.8% with LAI fluphenazine, 
and 91.7% with LAI zuclopenthixol (Figure 4). Together with 
LAI risperidone started at baseline, the oral formulations of 
risperidone, olanzapine, quetiapine, and aripiprazole (account-
ing for more than 90% of concurrent oral antipsychotic medi-
cation) were given at median doses of 6 mg/day, 20 mg/day, 
1200 mg/day, and 15 mg/day, respectively, throughout the 
study. Risperidone and olanzapine were also the most com-
mon oral agents used concomitantly with LAI fluphenazine 
and LAI zuclopenthixol, although at lower median doses 
(4 mg/day of risperidone and 10 mg/day of olanzapine).
health resource utilization  
and direct health care costs
Table 2 provides detailed results and the unit costs applied 
to resource utilization data to calculate direct costs per 
patient. The mean (median) total health care cost per patient 
per month during the study year among the 92 patients who 
started any LAI antipsychotic at baseline was €1407 (€897.7); 
this was greater among patients treated with LAI risperi-
done (€1487 [€998.4]) than with LAI fluphenazine (€938.3 
[€147.1]), or LAI zuclopenthixol (€904.3 [€391.3]).
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Figure 2 Kaplan–Meier description of the proportion of the sample surviving 
without relapse during follow‑up (n = 597).
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Medication costs represented 44.4% of mean total 
direct health care costs. LAI risperidone acquisition costs 
represented 39.4% of the mean total direct costs incurred 
by patients treated with this LAI formulation. Those from 
LAI fluphenazine or LAI zuclopenthixol accounted for no 
more than 1.2% of the mean total direct costs, whereas oral 
supplementation costs accounted for 6.4%, 10.8%, and 
33.6% of the mean total direct costs incurred by patients on 
LAI risperidone, LAI fluphenazine, and LAI zuclopenthixol, 
respectively.
Nonmedication costs represented 55.6% of mean total 
direct health care costs. Inpatient (general and psychiatric 
hospitalizations) and outpatient hospitalizations (including 
institutional support and day hospital stays) costs represented 
38.4% of the mean total direct costs (Table 2, Figure 5). 
Specifically, institutional support and day hospital stays 
represented a relevant contribution to mean total direct costs: 
€263.5 (€0) and €208.1 (€0), despite costs being incurred by 
only 7 and 18 patients, respectively. However, and despite 
their high unit costs, inpatient hospitalizations did not 
account for relevant costs because of their low incidence 
throughout the study year (10 out of 92 patients, 10.9%). 
Table 2 provides a detailed breakdown of resource utiliza-
tion data and costs.
Discussion
Patients included in this study showed an unfavorable clinical 
profile, including factors for bad prognosis that have been 
consistently associated with nonadherence. Importantly, the 
intervention made at baseline was associated with improved 
effectiveness, as denoted by the 9.2% of patients hospitalized 
during 1-year follow-up, compared with 20.9% of patients 
who had been hospitalized only within the prior 6 months. 
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Figure 3 Distribution of the doses of LAi risperidone at each study assessment among patients treated with this medication.
Abbreviation: LAi, long‑acting injectable.
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Figure 4 Kaplan–Meier description of the proportion of patients receiving 
concomitant oral antipsychotics together with LAi antipsychotics, regardless of 
whether the LAi antipsychotic was started at baseline or during the study.
Abbreviation: LAi, long‑acting injectable.
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Table 2 resource utilization and direct health care costs according to prescription of long‑acting antipsychotics at baseline
Antipsychotic drugsa Nb Average utilization  
(services/month)c,d
Unit cost  
(€/service)
Average total cost 
(€/patient/month)c,e
LAi antipsychotic treatment (any) 92 504.5 (519.3) [314.7]
 LAi risperidone 79 586.5 (519.4) [259.5]
 LAI fluphenazine 6 1.3 (1.2) [0.75]
 LAi zuclopenthixol 7 10.6 (11.9) [5.2]
Oral antipsychotic treatment 92 111.6 (36.8) [174.0]
Concomitant psychotropic drugsa
Anticholinergics 0.2 (0.0) [0.8]h
Antidepressants 5.0 (0.0) [21.1]h
Anxiolytics/hypnotics 2.1 (0.0) [3.8]h
Mood stabilizers 0.8 (0.0) [4.0]h
Other psychotropics 1.3 (0.0) [5.3]h
Nonpharmacologic therapies
institutional support 7 20.4 (6.0) 169.5 263.5 (0.0) [959.3]h
AcT/case management 18 4.4 (4.7) 40.5 34.4 (0.0) [108.3]h
group or individual psychoeducation 11 4.1 (6.0) 89.2 43.7 (0.0) [214.0]h
Family psychoeducation 10 1.5 (1.3) 121.7 19.9 (0.0) [76.8]h
group or individual psychotherapy 5 6.5 (8.6) 67.4 23.8 (0.0) [157.8]h
rehabilitation/occupational support 15 9.5 (6.2) 26.6 41.1 (0.0) [113.8]h
severe mental illness management program 1 1.1 (–) 58.2 0.7 (0.0) [6.6]h
Health care resources
inpatient hospitalization (general hospital) 3 1.9 (1.8) 225.4 13.8 (0.0) [95.6]h
inpatient hospitalization (psychiatric hospital) 7 3.7 (3.1) 161.1 45.8 (0.0) [204.4]h
emergency room visits 28 0.2 (0.2) 117.8 8.7 (0.0) [20.2]h
Day hospital 18 6.3 (6.2) 169.5 208.1 (0.0) [620.3]h
Psychiatric outpatient consultations 89 0.8 (0.3) 69.7,f 42.1g 36.3 (37.5) [15.3]
Other specialized outpatient consultations 18 0.2 (0.2) 51.3 2.0 (0.0) [5.6]h
Primary care outpatient consultations 67 0.6 (0.4) 18.0 8.3 (7.3) [8.1]
Visits to skilled nursing facilities 89 1.9 (1.3) 16.8 30.7 (29.7) [22.1]
home visits 15 0.3 (0.5) 21.4 1.0 (0.0) [4.7]h
Total monthly cost per patient
Patients started on any LAi antipsychotic 92 1407.0 (897.7) [1519.0]
Patients started on LAi risperidone 79 1487.0 (998.4) [1543.0]
Patients started on LAI fluphenazine 6 938.3 (147.1) [1763.0]
Patients started on LAi zuclopenthixol 7 904.3 (391.3) [931.8]
Notes: aUtilization and unit costs are not expressed because they varied from patient to patient and were calculated on an individual basis according to each patient’s 
pharmacologic treatment; bnumber of patients who used the resource at least once during the study year; cvalues are mean (median) [standard deviation]; dvalues are 
monthly averages among the patients who used the service at least once throughout the study year; evalues are averaged for the subgroup of 92 patients who started any 
LAi antipsychotic treatment at baseline visit; fcost of the first (initial contact) visit; gcost of subsequent (follow‑up) visits; hmedians have a value of zero if less than half of the 
patients used the resource.
Abbreviations: AcT, Assertive community Treatment; LAi, long‑acting injectable.
Although prestudy relapse incidence was not recorded, it 
is highly probable, based on the comparison of the pre-
posthospitalization rates, that the relapse incidence during 
the prior year was well above the 15.1% observed during 
follow-up. Given the unfavorable profile and the selection 
procedure, prescription of LAI antipsychotics at baseline 
(15.4%) was lower than anticipated. More than 9 in 10 of 
these LAI prescriptions were of risperidone (the only second-
generation agent commercially available as LAI when the 
data were collected), oral antipsychotic supplementation 
was maintained during 1 year in more than two thirds of 
patients, and the doses of both oral and LAI antipsychotics 
were close to their maximum-labeled doses and, therefore, 
associated with relevant costs. The information available 
on nonpharmacologic therapies, and health care resource 
utilization, indicates that the nonmedication direct costs of 
patients who started therapy with LAI antipsychotics in the 
year after the initial prescription were substantial, represent-
ing 55.6% of the mean total direct health care costs. Many 
of these facts are consistent with the relevant literature and 
have clinical implications.
The prescription of LAI antipsychotics has been 
 considered too low in many studies investigating their use to 
date,11–13,23 which is in agreement with the low utilization in 
this study. Together with the challenging clinical profile of 
the patients evaluated, these findings support the  generalized 
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view among psychiatrists that long-acting antipsychotics 
should be reserved for a small subgroup of patients and used 
only after a patient has repeatedly demonstrated difficulty 
adhering to an oral regimen and has had several relapses.11,24,25 
The cited studies also included nonadherent patients and, 
although they were performed in different cultural settings, 
the proportion of patients changed to long-acting antipsychot-
ics was also low and similar to the 15.4% observed in this 
study (10.6%25 and 17.6%11). In this vein, the high doses of 
LAI antipsychotics and the extensive use of oral antipsychotic 
supplementation suggest a restrictive use pattern reserved for 
the patients hardest to treat.26 This circumstance might also 
explain the doses employed; of note, more than one quarter 
of patients treated with LAI risperidone were above the maxi-
mum recommended dose of 50 mg every 2 weeks.27
Strikingly, the authors observed similar relapse rates in 
patients receiving LAI antipsychotics than in patients treated 
with oral antipsychotics. Some explanations can be cited for 
this somewhat paradoxical finding. For instance, LAI-treated 
patients could be in a worse condition than non-LAI patients, 
but they did not relapse more as they benefited from LAI 
antipsychotics. Alternatively, nonpharmacologic therapies 
might also have been effective in preventing relapse in some 
patients on oral antipsychotics. Importantly, whatever the 
reason, this study shows that even in the most challenging 
patients, relapse risk reduction is still clinically feasible if the 
strategies best suited for each individual are used.
The widespread concurrent use of oral supplementation 
may also have a clinical reading, in particular consider-
ing that risperidone was the agent used in nearly all cases, 
whose delayed onset of action is known to be inconvenient.28 
Because oral supplementation therapy should be maintained 
for at least 3 weeks after starting long-acting risperidone,27,29 
and because it was reserved for the most troublesome cases, 
the treating psychiatrists would refrain from ceasing oral 
therapy once a few weeks had elapsed since the switching, 
for fear of clinical destabilization of their more challenging 
patients,30 leading to a prolonged polypharmacy. In contrast, 
a much lower concurrent use of oral antipsychotics with 
long-acting risperidone has recently been reported after 
2 years in the electronic Schizophrenia Treatment Adherence 
Registry (e-STAR).31 Possible reasons for this divergence 
include differences in disease severity, selection criteria, 
and LAI risperidone  dosing. Patients in the e-STAR were 
not selected on the basis of nonadherence risk; some were 
receiving LAI risperidone before recruitment, and started 
and maintained it at lower doses than in the present study. 
It remains to be  elucidated whether prolonged oral antipsy-
chotic supplementation will be less common when other LAI 
second-generation antipsychotics that do not require an initial 
overlap with prior oral therapy are available. The prominent 
use of risperidone over first-generation LAI antipsychotics 
also supports the opinion that the unavailability of other 
second-generation LAI antipsychotics plays a role in their 
low utilization,32,33 as psychiatrists tend to prime the potential 
advantages of second-generation antipsychotics over the 
benefits of long-acting formulations.34
Few patients started LAI antipsychotics immediately 
after a relapse. Consistently, psychiatrists questioned about 
their attitudes toward long-acting antipsychotics, stated that 
these are not an appropriate option after a relapse,13 or for 
first-episode patients.12,13,26 This study has focused on patients 
undergoing changes of their therapeutic strategy related to 
nonadherence risk and it cannot address the relevant question 
of when is the optimal moment for starting long-acting antip-
sychotic therapy. There are reports suggesting that patients 
with experience of long-acting antipsychotics have a good 
opinion on them,35,36 yet potential biases of patients estab-
lished on LAI antipsychotics may distort this judgment.32,37 
Future research should focus on the use of LAI antipsychotics 
in stable patients with a favorable disease course, as these 
have been recently suggested as potential candidates in a 
survey of psychiatrists’ opinions.26
One reason alleged to avoid LAI antipsychotics is that 
they are associated with high treatment costs.13 While not 
opposing this belief, the monthly direct health care cost per 
patient in this study was substantially higher than the reported 
average costs of schizophrenia in Spain.19 However, the 
Concomitant psychotropic
medications
(0.7%)
Hospitalizations,
including institutional
support and day hospital
(38.4%)
Antispychotics
(43.8%)
Non pharmacological,
other than hospitalizations
(17.2%)
Figure 5 Pie chart showing the breakdown of direct health care costs throughout 
the study year incurred by patients who started a long‑acting injectable antipsychotic 
at recruitment (n = 92).
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present study selected a sample of challenging patients who 
probably require more resources than the average patient 
with schizophrenia and, furthermore, we did not account for 
direct nonmedical costs, which in the cited study represented 
as much as 47% of total direct costs. Interestingly, such cost 
analysis was done prior to licensing of LAI risperidone. In 
an even more recent report, LAI risperidone proved to be a 
cost-effective strategy despite the higher drug acquisition 
costs, because of the considerable reduction in hospital 
stays.38 Relapse is an important predictor of treatment costs 
for patients with schizophrenia. In the US Schizophrenia 
Care and Assessment Program (US-SCAP) study, the total 
direct health care costs of patients without any relapse were 
lower, but the costs of patients with multiple relapses more 
than doubled those reported by us.39
This research has some limitations. It is based on post hoc 
analyses and the results should be regarded as  exploratory. 
Comparisons of the outcomes of oral and long-acting  second 
generation antipsychotics is a research priority7 but this 
study cannot provide comparative data as the patients were 
not randomized to either treatment option. The small num-
ber of patients treated with either LAI fluphenazine or LAI 
zuclopenthixol limits the accuracy of their results, which has 
precluded a detailed explanation for these patients, compared 
with that made for patients treated with LAI risperidone. This 
study did not address some concerns, which in addition to a 
delayed onset of action, surround the use of long-acting antip-
sychotics: poor definition of the dose-response relationship, 
facilities and skills required for their storage and administra-
tion, the experience of coercion, the clinical circumstances 
other than nonadherence and relapse that grant the use of 
these formulations, or how should the reverse switch (from 
long-acting to oral) can best be accomplished. Furthermore, 
this study focused on direct costs and did not therefore collect 
data on indirect costs, which are substantial in this pathol-
ogy.19 Future research should address these uncertainties 
and explore the role of long-acting antipsychotics for the 
maintenance of patients with good levels of insight, who are 
immersed in the recovery process.
Conclusion
This study provides current data on the clinical and economic 
outcomes of patients with schizophrenia at risk of nonadher-
ence in clinical practice in Spain during the 12 months of the 
study period. It has shown that diminishing relapse in patients 
with long-standing schizophrenia involving therapeutic chal-
lenges related to nonadherence is feasible. It has also con-
firmed that long-acting antipsychotics are infrequently used. 
Most LAI antipsychotic prescriptions were of risperidone, the 
only atypical antipsychotic available as an LAI when the study 
was conducted. According to the observed mean total direct 
health care costs during the study period, medication costs 
were lower than nonmedication costs, the latter representing 
more than 55% of the mean total direct health care costs.
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